Cancer remains a major cause of death, and several malignancies—such as pancreatic ductal adenocarcinoma (PDAC)—remain highly resistant to immunotherapy due to a tumor microenvironment dominated by inflammation, fibrosis, and immune suppression. Among its key regulators are tumor-associated macrophages (TAMs), which can either sustain tissue repair or promote anti-tumor immunity. The ERC project MEFHISTO aims to uncover how macrophages balance these opposing functions by investigating a newly identified regulatory pathway, the PGE2-MEF2A axis, which acts as a molecular switch between cytotoxic and reparative inflammation. By combining advanced genomic, spatial, and functional analyses, the project will define how this axis is deregulated in cancer and how its modulation could restore immune control in resistant tumors like PDAC. Ultimately, MEFHISTO will provide a new conceptual framework for understanding and therapeutically harnessing inflammation, paving the way for next-generation immunotherapies.